BioSpace News Archive

Wilmington, Delaware, United States, Transparency Market Research Inc. – According to Transparency Market Research’s latest report on the global transcatheter embolization and occlusion devices market for the historical period 2017–2018 and forecast period 2019–2027.

In order to detect structural and functional proteins in cells of tissue samples, multiplexed staining technique is a common approach utilized.

Wilmington, Delaware, United States, Transparency Market Research Inc. – The global nasal polyps treatment market was valued at ~US$ 3.9 Bn in 2018, and is projected to reach ~US$ 6 Bn by 2027, expanding at a CAGR of ~5% from 2019 to 2027.

The microneedle drug delivery systems market has been predicted to grow at a noticeable pace during the forecast period.

Helsinn Group announces its participation in the upcoming IASLC 2022 World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer, taking place from 6-9 August in Vienna, Austria.

Bionomics Limited, a clinical stage biopharmaceutical company, is pleased to announce that the Company has received A$2,085,453.17 research and development tax incentive refund relating to the financial year ended June 2021.

Guardant Health Inc., a leading precision oncology company, and Blueprint Medicines Corporation announced they are presenting new data demonstrating that the EGFR C797X mutation is the most common resistance mechanism to osimertinib therapy for patients with advanced non-small cell lung cancer.

Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, announced financial results for the second quarter of 2022 and provided a general business update.

BD, a leading global medical technology company, along with Direct Relief and the National Association of Community Health Centers, announced they have awarded four community health centers with a total of $1.08 million to implement programs to support chronic disease management to underserved communities.

Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced the publication of a clinical utility study in The American Journal of Managed Care confirming Primary Care Physicians (PCPs) understand the value of KidneyIntelX™ in determining appropriate guideline-recommended treatment decisions in their adult patients with type 2 diabetes (T2D) and early chronic kidney disease stages 1-3 (diabetic kidney disease).